Publication date: Nov 03, 2024
This study is to evaluate the effectiveness and safety of a 9-month MDR-END regimen as a treatment for fluoroquinolone-sensitive multidrug resistant pulmonary tuberculosis in the real-world clinical setting. It will be conducted as a non-interventional, prospective, single group, multicenter design. Subjects who are considered to meet the inclusion /exclusion criteria will receive MDR-END regimen for 9 months (or 12 months) during the treatment period according to the 5th edition of the Korean Guidelines for Tuberculosis, and will be followed-up for 12 months after the end of treatment.
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Delamanid |
| drug | DRUGBANK | Linezolid |
| drug | DRUGBANK | Levofloxacin |
| drug | DRUGBANK | Pyrazinamide |
| disease | MESH | Multi-Drug Resistant Tuberculosis |
| disease | MESH | pulmonary tuberculosis |
| disease | MESH | Tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | MESH | hypersensitivity |
| disease | MESH | contraindications |
| disease | IDO | history |
| disease | MESH | optic neuritis |
| drug | DRUGBANK | Galactose |
| drug | DRUGBANK | Tilactase |
| drug | DRUGBANK | Dextrose unspecified form |